H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Nuvation Bio to $7 from $8 and keeps a Buy rating on the shares. The firm says the pooled TRUST-I and TRUST-II results support FDA approval. However, it trimmed the price target to reflect Nuvation’s higher spending.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB: